Literature DB >> 26978478

Novel Time-Resolved Fluorescence Europium Nanoparticle Immunoassay for Detection of Human Immunodeficiency Virus-1 Group O Viruses Using Microplate and Microchip Platforms.

Mohan Kumar Haleyur Giri Setty1, Jikun Liu1, Prerna Mahtani1, Panhe Zhang1, Bingchen Du1, Viswanath Ragupathy1, Krishnakumar Devadas1, Indira K Hewlett1.   

Abstract

Accurate detection and quantification of HIV-1 group O viruses have been challenging for currently available HIV assays. We have developed a novel time-resolved fluorescence (TRF) europium nanoparticle immunoassay for HIV-1 group O detection using a conventional microplate enzyme-linked immunosorbent assay (ELISA) and a microchip platform. We screened several antibodies for optimal reactivity with several HIV-1 group O strains and identified antibodies that can detect all the strains of HIV-1 group O that were available for testing. The antibodies were used to develop a conventional ELISA format assay and an in-house developed europium nanoparticle-based assay for sensitivity. The method was evaluated on both microwell plate and microchip platforms. We identified two specific and sensitive antibodies among the six we screened. The antibodies, C65691 and ANT-152, were able to quantify 15 and detect all 17 group O viruses, respectively, as they were broadly cross-reactive with all HIV-1 group O strains and yielded better signals compared with other antibodies. We have developed a sensitive assay that reflects the actual viral load in group O samples by using an appropriate combination of p24 antibodies that enhance group O detection and a highly sensitive TRF-based europium nanoparticle for detection. The combination of ANT-152 and C65690M in the ratio 3:1 was able to give significantly higher signals in our europium-based assay compared with using any single antibody.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26978478      PMCID: PMC4892209          DOI: 10.1089/aid.2014.0351

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  42 in total

1.  Phylogenetic analysis of 49 newly derived HIV-1 group O strains: high viral diversity but no group M-like subtype structure.

Authors:  P Roques; D L Robertson; S Souquière; F Damond; A Ayouba; I Farfara; C Depienne; E Nerrienet; D Dormont; F Brun-Vézinet; F Simon; P Mauclère
Journal:  Virology       Date:  2002-10-25       Impact factor: 3.616

2.  Unequal detection of HIV type 1 group O infection by simple rapid tests.

Authors:  Agnès Gautheret-Dejean; Serge Mesmin-Poho; Jacques Birguel; Véronique Lemée; Jean-Marie Huraux; Jean-Christophe Plantier
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

3.  Further evidence of the presence of genetically aberrant HIV-1 strains in Cameroon and Gabon.

Authors:  W Janssens; J N Nkengasong; L Heyndrickx; K Fransen; P M Ndumbe; E Delaporte; M Peeters; J L Perret; A Ndoumou; C Atende
Journal:  AIDS       Date:  1994-07       Impact factor: 4.177

4.  HIV-1 group O infection in Cameroon from 2006 to 2013: Prevalence, genetic diversity, evolution and public health challenges.

Authors:  Christian Julian Villabona-Arenas; Jenny Domyeum; Fatima Mouacha; Christelle Butel; Eric Delaporte; Martine Peeters; Eitel Mpoudi-Ngole; Avelin Fobang Aghokeng
Journal:  Infect Genet Evol       Date:  2015-09-11       Impact factor: 3.342

5.  Human immunodeficiency virus (HIV) subtype surveillance of African-born persons at risk for group O and group N HIV infections in the United States.

Authors:  P S Sullivan; A N Do; D Ellenberger; C P Pau; S Paul; K Robbins; M Kalish; C Storck; C A Schable; H Wise; C Tetteh; J L Jones; J McFarland; C Yang; R B Lal; J W Ward
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

6.  Nanoparticle-based immunoassays for sensitive and early detection of HIV-1 capsid (p24) antigen.

Authors:  Shixing Tang; Indira Hewlett
Journal:  J Infect Dis       Date:  2010-04-15       Impact factor: 5.226

7.  Reduction of the diagnostic window with a new combined p24 antigen and human immunodeficiency virus antibody screening assay.

Authors:  L Gürtler; A Mühlbacher; U Michl; H Hofmann; G G Paggi; V Bossi; R Thorstensson; R G-Villaescusa; A Eiras; J M Hernandez; W Melchior; F Donie; B Weber
Journal:  J Virol Methods       Date:  1998-11       Impact factor: 2.014

8.  Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate.

Authors:  M Vanden Haesevelde; J L Decourt; R J De Leys; B Vanderborght; G van der Groen; H van Heuverswijn; E Saman
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

Review 9.  HIV-1 Group O Origin, Evolution, Pathogenesis, and Treatment: Unraveling the Complexity of an Outlier 25 Years Later.

Authors:  Shannon Bush; Denis M Tebit
Journal:  AIDS Rev       Date:  2015 Jul-Sep       Impact factor: 2.500

10.  Inaccurate diagnosis of HIV-1 group M and O is a key challenge for ongoing universal access to antiretroviral treatment and HIV prevention in Cameroon.

Authors:  Avelin F Aghokeng; Eitel Mpoudi-Ngole; Henriette Dimodi; Arrah Atem-Tambe; Marcel Tongo; Christelle Butel; Eric Delaporte; Martine Peeters
Journal:  PLoS One       Date:  2009-11-06       Impact factor: 3.240

View more
  3 in total

1.  Cross-Subtype Detection of HIV-1 Capsid p24 Antigen Using a Sensitive Europium Nanoparticle Assay.

Authors:  Mohan Kumar Haleyur Giri Setty; Aditya Kurdekar; Prerna Mahtani; Jikun Liu; Indira K Hewlett
Journal:  AIDS Res Hum Retroviruses       Date:  2019-01-14       Impact factor: 2.205

2.  Sub-picogram level sensitivity in HIV diagnostics achieved with the europium nanoparticle immunoassay through metal enhanced fluorescence.

Authors:  Aditya Kurdekar; L A Avinash Chunduri; Mohan Kumar Haleyurgirisetty; Indira K Hewlett; Venkataramaniah Kamisetti
Journal:  Nanoscale Adv       Date:  2018-08-24

Review 3.  Microfluidic devices for detection of RNA viruses.

Authors:  Arefeh Basiri; Arash Heidari; Melina Farshbaf Nadi; Mohammad Taha Pahlevan Fallahy; Sasan Salehi Nezamabadi; Mohammadreza Sedighi; Amene Saghazadeh; Nima Rezaei
Journal:  Rev Med Virol       Date:  2020-08-26       Impact factor: 11.043

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.